Sticking to evidence-based and strengthening innovation, the development of traditional Chinese medicine ushers in a bright moment

In November 2019, the "2019 China traditional Chinese medicine brand building conference and China traditional Chinese medicine brand press conference" held by China traditional Chinese Medicine Association was successfully held in Beijing, at which the "2019 China traditional Chinese medicine brand" including 20 clinically valuable Chinese patent medicine brands was released Before that, the national pharmaceutical economic information release and mifanghui annual meeting, known as the "wind vane for the development of Chinese pharmaceutical industry" by the industry, also announced the award list of 2019 "Chinese pharmaceutical brand list" once every three years Xi Jinping, general secretary of the CPC Central Committee, once said that Chinese medicine contains the concept of health preservation and practical experience of the Chinese nation for thousands of years, and is a treasure of Chinese civilization, which embodies the broad wisdom of the Chinese people and the Chinese nation In recent years, a number of policies, including the opinions on promoting the inheritance and innovation of traditional Chinese medicine, have continued to promote the inheritance and development of traditional Chinese medicine in China and accelerate the scientific research and innovation of traditional Chinese medicine But at the same time, due to the weakness of basic research, the lack of evidence-based evidence, and the continuous questioning of clinical efficacy and safety, the continuous and healthy development of Chinese medicine is seriously affected and restricted In order to build Chinese traditional medicine brand, lead the revitalization and high-quality development of Chinese medicine cause, China Association of traditional Chinese medicine held "2019 Chinese traditional medicine brand building conference and Chinese traditional medicine brand press conference" At the meeting, Liu Zhanglin, executive vice president of China Association of traditional Chinese medicine, said that strengthening evidence-based medicine research has become the only way for the development of Chinese patent medicine Based on this, according to the principles and standards of "high level of clinical benefit evidence, clinical achievements published in journals with high impact factors or recommended by domestic and foreign guidelines", China Association of traditional Chinese medicine selected the first 20 brands of Chinese patent medicines with clinical value "with definite efficacy, safe and reliable, sufficient evidence and high quality" Among them, zhizhikang, which is promoted by AstraZeneca, is one of the "20 brands of Chinese patent medicines with clinical value" It is understood that zhizhikang, originated from the medicinal Monascus, is the only natural lipid regulating drug with clinical hard end-point benefit in China, which has completed the second phase clinical research of FDA in the United States and recognized at home and abroad Over the past 20 years, a large number of clinical data have been accumulated, including large-scale clinical evidence-based medicine research such as China coronary heart disease secondary prevention research (CCSPS) It has been confirmed that Xuezhikang is effective in regulating lipid and reducing the incidence of cardiovascular events, with fewer adverse reactions, more moderate and safe To give full play to its unique advantages, traditional Chinese medicine has always been benefiting the grassroots With its advantages of natural, cheap, small side effects and unique efficacy, traditional Chinese medicine has a profound mass base, especially in the prevention and treatment of chronic diseases such as dyslipidemia, hypertension, diabetes, cardiovascular and cerebrovascular diseases The outline of healthy China 2030 program points out that by 2030, the health management of chronic diseases in the whole population and life cycle should be basically realized Therefore, in the context of aging population and increasing incidence rate of chronic diseases, Chinese medicine will play an irreplaceable role in achieving "healthy China" Taking the treatment and management of dyslipidemia as an example, Xuezhikang, a natural lipid regulating drug, is made of special red koji fermented by modern technology Its 13 kinds of natural statins and their homologues, together with flavonoids, ergosterol and unsaturated fatty acids, play a comprehensive role in lipid regulation Recently, Xuezhikang's Monascus technology has obtained Canadian patents for new Monascus compounds and lipid regulating applications Based on the clear efficacy and safety of lipid regulation, zhizhikang has been recommended as a first-line lipid management drug in the guidelines for the prevention and treatment of adult dyslipidemia in China (revised in 2016), and included in the latest version of China's national directory of drugs for basic medical insurance and industrial injury insurance and the national directory of basic drugs In November 2019, in the national pharmaceutical economic information release and annual meeting of mifanghui, which is known as the "wind vane for the development of China's pharmaceutical industry", zhizhikang was listed in the "Chinese medicine brand list" of 2019, once again proving the recognition of both doctors and patients on the safety and efficacy of zhizhikang Traditional Chinese medicine has made outstanding contributions to the prosperity of the Chinese nation, and also has a positive impact on the progress of world civilization The 20 brands of Chinese patent medicine with clinical value, including zhizhikang capsule, are to prove the efficacy with evidence-based method, cultivate the brand with clinical value and lead the industrial development with brand We believe that as long as we give full play to the unique advantages of traditional Chinese medicine in disease prevention, treatment and rehabilitation, adhere to the path of evidence-based medicine, and lead the innovation and development of traditional Chinese medicine with a rigorous and objective attitude, we can continue to promote the inheritance and innovation of traditional Chinese Medicine and promote the development of Chinese medicine events.